Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Centro de Investigación Biomédica en Red · Clinica Universidad de Navarra · +29 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
212
total citations
- FWCI
- 203.16
- Percentile
- 100%
- References
- 36
Citations per year
Authors
172- BSBruno SangroCorresponding
Centro de Investigación Biomédica en Red, Clinica Universidad de Navarra, Universidad de Navarra
- MKMasatoshi Kudo
Kindai University
- JPJoseph P. Erinjeri
Memorial Sloan Kettering Cancer Center
- SQShukui Qin
Nanjing General Hospital of Nanjing Military Command, Jiangsu Cancer Hospital
- ZRZhenggang Ren
Fudan University, Zhongshan Hospital
Topics & keywords
Topics
Keywords
- Durvalumab
- Medicine
- Bevacizumab
- Placebo
- Clinical endpoint
- Regimen
- Internal medicine
- Oncology
No related works found for this paper.